Directory

Discover detailed profiles of PoC companies.

Bio Design Lab Co., Ltd.

Next-Generation Viral Vector Platforms for Safe and Efficient Gene & Cell Therapy

Specialization

Synthetic Biology

Gene Therapy Platform

Keywords

Viral Vector
Gene & Cell Therapy

Development of RetroNext and LentiNext, next-generation viral vector platforms utilizing synthetic biology and systems engineering.
Engineered for maximum gene delivery efficiency and unprecedented vector safety, resolving risks of oncogene activation and tumor suppressor disruption.
Platforms designed to replace conventional vectors through optimized insertion control, minimizing unwanted gene integration.
Provides core technologies enabling safer and more effective gene therapy, cell therapy, and immune-oncology applications.

(1) Owned Technology

RetroNext & LentiNext Platforms — engineered retroviral/lentiviral vectors that significantly reduce insertional mutagenesis risk.
Systems-level genetic design and bio-part assembly method improving safety and performance across therapeutic applications.
Proprietary computational design and experimental validation library for vector customization.

(2) Applied Products

Gene and cell therapy vectors for CAR-T/NK/M cells.
Immune-oncology therapies utilizing next-gen viral delivery systems.
Antibody-producing cell lines and custom vector design services for biopharma partners.

(1) Problem Definition / Development Background

Existing viral vectors show low delivery efficiency and high safety risks, often causing insertional mutagenesis.
FDA and EMA reviews emphasize the urgent need for safer gene delivery methods.

(2) Value Proposition / Solution

Safety breakthrough: Reduces insertion frequency in high-risk regions (TSS, CpG islands, gene domains) by more than 70%.
Enhanced efficiency: 250–2000% higher gene delivery capability compared to conventional vectors.
Scalable and modular: Compatible with existing manufacturing and clinical-grade systems.

Global first-in-class safety platform addressing FDA concerns on vector-induced malignancies.
12× higher delivery efficiency and 10× higher expression performance vs. existing lentiviral vectors.
Strong IP portfolio built on multi-plasmid synthetic designs and scalable vector production.
Positioned to lead the next-generation viral vector market projected to grow at a CAGR of 34% through 2027.

Successful technology transfer cases valued at USD 1.4 billion in the gene and cell therapy sector.
Established collaborations with over 10 domestic and global biopharma partners, including top-10 CDMOs.
Expanding pipeline for CAR-T/NK and antibody-producing cell lines.
Preparing for Series C funding to scale manufacturing and regulatory approvals.

(1) PoC Progress

(2) Global Expansion

Ongoing joint development projects with overseas biotech companies in the U.S. and EU.
Actively engaging in technology transfer and co-development agreements for large-scale manufacturing.
Expanding global partnerships for clinical trials and licensing opportunities.